Insider Trading activities at Ariad Pharmaceuticals Inc (ARIA)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ariad Pharmaceuticals Inc (ARIA) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ariad Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 884731.

Total stock buying since 2014: $6,472,847.
Total stock sales since 2014: $12,625,774.
Total stock option exercises since 2014: $5,193,726.

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at *Ariad Pharmaceuticals Inc* (*ARIA*).
	Insider Buying		Insider Sales		Option Exercises
Year	Shares	Value	Shares	Value	Shares	Value
2017	0	$0	32,000	$760,960	157,266	$250,240
2016	88,089	$499,991	784,465	$6,444,543	971,625	$1,909,599
2015	52,600	$342,273	566,814	$4,702,565	1,613,254	$1,912,838
2014	963,000	$5,630,583	114,808	$717,706	333,675	$1,121,049

Table 2. Monthly summary of insider trading at *Ariad Pharmaceuticals Inc* (*ARIA*).
Trading Period	Insider Buying		Insider Sales		Option Exercises
year-month	Shares	Value	Shares	Value	Shares	Value
2017-01	0	$0	32,000	$760,960	157,266	$250,240
2016-10	0	$0	67,022	$825,575	0	$0
2016-09	0	$0	88,119	$1,087,245	86,869	$464,265
2016-08	0	$0	44,436	$466,033	25,000	$192,250
2016-07	0	$0	79,708	$607,846	128,022	$237,703
2016-06	0	$0	214,830	$1,739,251	203,985	$963,931
2016-05	26,990	$199,995	17,762	$143,428	0	$0
2016-04	0	$0	21,409	$157,869	66,002	$0
2016-03	0	$0	145,578	$908,483	201,416	$51,450
2016-02	61,099	$299,996	105,601	$508,813	260,331	$0
2015-12	0	$0	0	$0	602,500	$0
2015-09	0	$0	45,696	$302,440	132,500	$0
2015-08	0	$0	34,126	$341,260	0	$0
2015-07	0	$0	31,800	$271,606	99,600	$0
2015-06	0	$0	0	$0	19,167	$0
2015-05	0	$0	60,000	$528,000	60,000	$453,600
2015-04	0	$0	123,766	$1,175,777	0	$0
2015-03	0	$0	116,788	$1,022,831	358,114	$1,284,919
2015-02	25,000	$170,850	154,638	$1,060,651	341,373	$174,319
2015-01	27,600	$171,423	0	$0	0	$0
2014-12	27,600	$174,484	0	$0	0	$0
2014-11	27,600	$170,013	1,749	$12,243	0	$0
2014-10	27,600	$144,167	0	$0	0	$0
2014-09	27,600	$171,821	109,346	$679,851	234,075	$1,121,049

Table 3. Detailed insider trading at *Ariad Pharmaceuticals Inc* (*ARIA*)
Trade Date	Insider Name	Trade Type	Shares	Price ($)	Value ($)
2017-01-31	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	29,333	.00	0
2017-01-31	Clackson Timothy P (President, R&D, CSO)	Option Ex	29,333	.00	0
2017-01-13	Panayiotopoulos Paris (President and CEO)	Option Ex	66,600	.00	0
2017-01-09	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	32,000	23.78	760,960
2017-01-09	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	32,000	7.82	250,240
2016-10-24	Clackson Timothy P (President, R&D, CSO)	Sale	19,638	9.56	187,739
2016-10-03	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	47,384	13.46	637,836
2016-09-28	Clackson Timothy P (President, R&D, CSO)	Sale	8,750	13.98	122,307
2016-09-26	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	10,000	.00	0
2016-09-26	Clackson Timothy P (President, R&D, CSO)	Option Ex	17,500	.00	0
2016-09-22	Clackson Timothy P (President, R&D, CSO)	Sale	20,000	13.43	268,540
2016-09-15	Clackson Timothy P (President, R&D, CSO)	Sale	59,369	11.73	696,398
2016-09-15	Clackson Timothy P (President, R&D, CSO)	Option Ex	59,369	7.82	464,265
2016-08-22	Clackson Timothy P (President, R&D, CSO)	Sale	19,436	10.47	203,533
2016-08-12	Clackson Timothy P (President, R&D, CSO)	Sale	25,000	10.50	262,500
2016-08-12	Clackson Timothy P (President, R&D, CSO)	Option Ex	25,000	7.69	192,250
2016-07-22	Clackson Timothy P (President, R&D, CSO)	Sale	18,286	8.11	148,226
2016-07-13	Panayiotopoulos Paris (President and CEO)	Option Ex	66,600	.00	0
2016-07-01	Clackson Timothy P (President, R&D, CSO)	Sale	61,422	7.48	459,620
2016-07-01	Clackson Timothy P (President, R&D, CSO)	Option Ex	61,422	3.87	237,703
2016-06-28	Cole Hugh M (SVP, Chief Business Officer)	Sale	6,012	7.05	42,384
2016-06-27	Cole Hugh M (SVP, Chief Business Officer)	Option Ex	19,166	.00	0
2016-06-22	Clackson Timothy P (President, R&D, CSO)	Sale	23,999	7.28	174,640
2016-06-15	Lavidas Athanese	Sale	46,250	8.24	381,146
2016-06-15	Lavidas Athanese	Option Ex	46,250	6.25	289,062
2016-06-14	Radaelli Massimo	Sale	6,250	8.13	50,831
2016-06-14	Radaelli Massimo	Option Ex	6,250	4.91	30,687
2016-06-14	Lavidas Athanese	Sale	20,000	8.14	162,860
2016-06-14	Lavidas Athanese	Option Ex	20,000	6.44	128,800
2016-06-13	Radaelli Massimo	Sale	79,731	8.25	657,860
2016-06-13	Radaelli Massimo	Option Ex	79,731	5.39	429,989
2016-06-13	Lavidas Athanese	Sale	10,000	8.21	82,050
2016-06-13	Lavidas Athanese	Option Ex	10,000	5.49	54,900
2016-06-10	Radaelli Massimo	Sale	22,588	8.30	187,480
2016-06-10	Radaelli Massimo	Option Ex	22,588	1.35	30,493
2016-05-23	Clackson Timothy P (President, R&D, CSO)	Sale	17,762	8.07	143,428
2016-05-12	Panayiotopoulos Paris (President and CEO)	Buy	26,990	7.41	199,995
2016-04-29	Cantor Maria E (SVP, Corporate Affairs)	Option Ex	13,334	.00	0
2016-04-29	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	17,334	.00	0
2016-04-29	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	17,334	.00	0
2016-04-29	Duvall Martin J (EVP, CCO)	Option Ex	18,000	.00	0
2016-04-22	Clackson Timothy P (President, R&D, CSO)	Sale	21,409	7.37	157,869
2016-03-22	Clackson Timothy P (President, R&D, CSO)	Sale	23,834	6.58	156,875
2016-03-21	Haluska Frank (SVP, Clinical R&D, CMO)	Sale	3,575	6.47	23,115
2016-03-21	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	4,000	6.47	25,872
2016-03-21	Fitzgerald Edward M (Executive VP)	Sale	5,417	6.47	35,037
2016-03-21	Berstein David L (SVP, Chief IP Counsel)	Sale	2,375	6.47	15,356
2016-03-19	Cantor Maria E (SVP, Corporate Affairs)	Sale	3,575	6.46	23,101
2016-03-19	Cantor Maria E (SVP, Corporate Affairs)	Option Ex	6,500	.00	0
2016-03-19	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	6,500	.00	0
2016-03-19	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	8,000	.00	0
2016-03-19	Duvall Martin J (EVP, CCO)	Sale	4,000	6.47	25,868
2016-03-19	Duvall Martin J (EVP, CCO)	Option Ex	8,000	.00	0
2016-03-19	Fitzgerald Edward M (Executive VP)	Option Ex	10,833	.00	0
2016-03-19	Clackson Timothy P (President, R&D, CSO)	Sale	5,417	6.47	35,037
2016-03-19	Clackson Timothy P (President, R&D, CSO)	Option Ex	10,833	.00	0
2016-03-19	Berstein David L (SVP, Chief IP Counsel)	Option Ex	4,750	.00	0
2016-03-16	Cole Hugh M (SVP, Chief Business Officer)	Option Ex	7,500	6.21	46,575
2016-03-15	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	3,750	1.30	4,875
2016-03-03	Cantor Maria E (SVP, Corporate Affairs)	Sale	9,625	6.12	58,866
2016-03-03	Haluska Frank (SVP, Clinical R&D, CMO)	Sale	10,588	6.11	64,735
2016-03-03	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	9,625	6.12	58,856
2016-03-03	Duvall Martin J (EVP, CCO)	Sale	9,625	6.12	58,866
2016-03-03	Fitzgerald Edward M (Executive VP, CFO)	Sale	9,625	6.12	58,866
2016-03-03	Clackson Timothy P (President, R&D, CSO)	Sale	9,625	6.12	58,866
2016-03-03	Berstein David L (SVP, Chief IP Counsel)	Sale	9,625	6.12	58,885
2016-03-02	Clackson Timothy P (President, R&D, CSO)	Sale	25,047	6.00	150,282
2016-03-01	Cantor Maria E (SVP, Corporate Affairs)	Option Ex	19,250	.00	0
2016-03-01	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	19,250	.00	0
2016-03-01	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	19,250	.00	0
2016-03-01	Duvall Martin J (EVP, CCO)	Option Ex	19,250	.00	0
2016-03-01	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	19,250	.00	0
2016-03-01	Clackson Timothy P (President, R&D, CSO)	Option Ex	19,250	.00	0
2016-03-01	Berstein David L (SVP, Chief IP Counsel)	Option Ex	19,250	.00	0
2016-02-18	Desrosier Thomas (EVP, General Counsel)	Option Ex	55,000	.00	0
2016-02-01	Panayiotopoulos Paris (President and CEO)	Buy	61,099	4.91	299,996
2016-02-01	Cantor Maria E (SVP, Corporate Affairs)	Sale	16,133	4.87	78,551
2016-02-01	Cantor Maria E (SVP, Corporate Affairs)	Option Ex	29,333	.00	0
2016-02-01	Haluska Frank (SVP, Clinical R&D, CMO)	Sale	16,133	4.81	77,583
2016-02-01	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	29,333	.00	0
2016-02-01	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	14,667	4.81	70,548
2016-02-01	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	29,333	.00	0
2016-02-01	Duvall Martin J (EVP, CCO)	Sale	14,667	4.81	70,577
2016-02-01	Duvall Martin J (EVP, CCO)	Option Ex	29,333	.00	0
2016-02-01	Fitzgerald Edward M (Executive VP, CFO)	Sale	14,667	4.81	70,518
2016-02-01	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	29,333	.00	0
2016-02-01	Clackson Timothy P (President, R&D, CSO)	Sale	14,667	4.81	70,518
2016-02-01	Clackson Timothy P (President, R&D, CSO)	Option Ex	29,333	.00	0
2016-02-01	Berstein David L (SVP, Chief IP Counsel)	Sale	14,667	4.81	70,518
2016-02-01	Berstein David L (SVP, Chief IP Counsel)	Option Ex	29,333	.00	0
2015-12-31	Berger Harvey J M D (Chairman & CEO)	Option Ex	602,500	.00	0
2015-09-28	Cantor Maria E (SVP, Corporate Affairs)	Sale	5,000	6.46	32,325
2015-09-28	Haluska Frank (SVP, Clinical R&D, CMO)	Sale	5,500	6.46	35,502
2015-09-28	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	5,000	6.46	32,315
2015-09-28	Duvall Martin J (EVP, CCO)	Sale	5,000	6.46	32,315
2015-09-28	Fitzgerald Edward M (Executive VP, CFO)	Sale	8,750	6.46	56,551
2015-09-28	Clackson Timothy P (President, R&D, CSO)	Sale	8,750	6.46	56,560
2015-09-28	Berstein David L (SVP, Chief IP Counsel)	Sale	5,000	6.46	32,315
2015-09-24	Cantor Maria E (SVP, Corporate Affairs)	Option Ex	10,000	.00	0
2015-09-24	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	10,000	.00	0
2015-09-24	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	10,000	.00	0
2015-09-24	Duvall Martin J (EVP, CCO)	Option Ex	10,000	.00	0
2015-09-24	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	17,500	.00	0
2015-09-24	Clackson Timothy P (President, R&D, CSO)	Option Ex	17,500	.00	0
2015-09-24	Berstein David L (SVP, Chief IP Counsel)	Option Ex	10,000	.00	0
2015-09-24	Berger Harvey J M D (Chairman & CEO)	Option Ex	47,500	.00	0
2015-09-01	Cantor Maria E (SVP, Corporate Affairs)	Sale	2,696	9.11	24,557
2015-08-28	Cantor Maria E (SVP, Corporate Affairs)	Sale	1,268	10.00	12,680
2015-08-28	Fitzgerald Edward M (Executive VP, CFO)	Sale	32,858	10.00	328,580
2015-07-16	Cantor Maria E (SVP, Corporate Affairs)	Sale	4,000	8.54	34,160
2015-07-16	Haluska Frank (SVP, Clinical R&D, CMO)	Sale	4,400	8.54	37,575
2015-07-16	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	4,000	8.54	34,164
2015-07-16	Duvall Martin J (EVP, CCO)	Sale	1,400	8.54	11,955
2015-07-16	Fitzgerald Edward M (Executive VP, CFO)	Sale	7,000	8.54	59,794
2015-07-16	Clackson Timothy P (President, R&D, CSO)	Sale	7,000	8.54	59,794
2015-07-16	Berstein David L (SVP, Chief IP Counsel)	Sale	4,000	8.54	34,164
2015-07-15	Cantor Maria E (SVP, Corporate Affairs)	Option Ex	8,000	.00	0
2015-07-15	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	8,000	.00	0
2015-07-15	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	8,000	.00	0
2015-07-15	Duvall Martin J (EVP, CCO)	Option Ex	2,800	.00	0
2015-07-15	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	14,000	.00	0
2015-07-15	Clackson Timothy P (President, R&D, CSO)	Option Ex	14,000	.00	0
2015-07-15	Berstein David L (SVP, Chief IP Counsel)	Option Ex	8,000	.00	0
2015-07-15	Berger Harvey J M D (Chairman & CEO)	Option Ex	36,800	.00	0
2015-06-25	Cole Hugh M (SVP, Chief Business Officer)	Option Ex	19,167	.00	0
2015-05-01	Fitzgerald Edward M (Executive VP, CFO)	Sale	60,000	8.80	528,000
2015-05-01	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	60,000	7.56	453,600
2015-04-23	Clackson Timothy P (President, R&D, CSO)	Sale	123,766	9.50	1,175,777
2015-03-26	Berger Harvey J M D (Chairman & CEO)	Option Ex	150,000	7.56	1,134,000
2015-03-23	Cantor Maria E (SVP, Corporate Affairs and HR)	Sale	4,033	8.55	34,490
2015-03-23	Haluska Frank (SVP, Clinical R&D, CMO)	Sale	3,300	8.55	28,228
2015-03-23	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	3,000	8.55	25,662
2015-03-23	Duvall Martin J (EVP, CCO)	Sale	834	8.57	7,144
2015-03-23	Fitzgerald Edward M (Executive VP, CFO)	Sale	4,167	8.55	35,632
2015-03-23	Clackson Timothy P (President, R&D, CSO)	Sale	6,667	8.55	57,016
2015-03-23	Clackson Timothy P (President, R&D, CSO)	Option Ex	13,333	.00	0
2015-03-23	Berstein David L (SVP, Chief IP Counsel)	Sale	2,000	8.56	17,118
2015-03-20	Cantor Maria E (SVP, Corporate Affairs and HR)	Sale	3,575	8.85	31,628
2015-03-20	Cantor Maria E (SVP, Corporate Affairs and HR)	Option Ex	7,333	.00	0
2015-03-20	Haluska Frank (SVP, Clinical R&D, CMO)	Sale	3,575	8.85	31,635
2015-03-20	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	6,000	.00	0
2015-03-20	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	4,000	8.85	35,392
2015-03-20	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	6,000	.00	0
2015-03-20	Duvall Martin J (EVP, CCO)	Sale	4,000	8.85	35,380
2015-03-20	Duvall Martin J (EVP, CCO)	Option Ex	1,667	.00	0
2015-03-20	Fitzgerald Edward M (Executive VP, CFO)	Sale	5,417	8.84	47,907
2015-03-20	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	8,333	.00	0
2015-03-20	Clackson Timothy P (President, R&D, CSO)	Sale	5,417	8.84	47,907
2015-03-20	Berstein David L (SVP, Chief IP Counsel)	Sale	2,375	8.85	21,025
2015-03-20	Berstein David L (SVP, Chief IP Counsel)	Option Ex	4,000	.00	0
2015-03-20	Berger Harvey J M D (Chairman & CEO)	Option Ex	34,000	.00	0
2015-03-19	Cantor Maria E (SVP, Corporate Affairs and HR)	Sale	9,346	9.00	84,114
2015-03-19	Cantor Maria E (SVP, Corporate Affairs and HR)	Option Ex	14,375	1.54	22,137
2015-03-19	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	6,500	.00	0
2015-03-19	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	8,000	.00	0
2015-03-19	Duvall Martin J (EVP, CCO)	Option Ex	8,000	.00	0
2015-03-19	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	10,833	.00	0
2015-03-19	Clackson Timothy P (President, R&D, CSO)	Sale	20,657	9.00	185,913
2015-03-19	Clackson Timothy P (President, R&D, CSO)	Option Ex	31,490	3.78	119,032
2015-03-19	Berstein David L (SVP, Chief IP Counsel)	Option Ex	4,750	.00	0
2015-03-19	Berger Harvey J M D (Chairman & CEO)	Option Ex	36,000	.00	0
2015-03-16	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	34,425	8.62	296,640
2015-03-16	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	7,500	1.30	9,750
2015-02-20	Clackson Timothy P (President, R&D, CSO)	Sale	49,035	8.00	392,280
2015-02-20	Clackson Timothy P (President, R&D, CSO)	Option Ex	49,035	3.56	174,319
2015-02-12	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.90	86,275
2015-02-11	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.77	84,575
2015-02-02	Cantor Maria E (SVP, Corporate Affairs and HR)	Sale	16,134	6.33	102,095
2015-02-02	Cantor Maria E (SVP, Corporate Affairs and HR)	Option Ex	29,334	.00	0
2015-02-02	Haluska Frank (SVP, Clinical R&D, CMO)	Sale	16,134	6.33	102,112
2015-02-02	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	29,334	.00	0
2015-02-02	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	14,667	6.33	92,827
2015-02-02	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	29,334	.00	0
2015-02-02	Duvall Martin J (EVP, CCO)	Sale	14,667	6.33	92,827
2015-02-02	Duvall Martin J (EVP, CCO)	Option Ex	29,334	.00	0
2015-02-02	Fitzgerald Edward M (Executive VP, CFO)	Sale	14,667	6.33	92,856
2015-02-02	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	29,334	.00	0
2015-02-02	Clackson Timothy P (President, R&D, CSO)	Sale	14,667	6.33	92,827
2015-02-02	Clackson Timothy P (President, R&D, CSO)	Option Ex	29,334	.00	0
2015-02-02	Berstein David L (SVP, Chief IP Counsel)	Sale	14,667	6.33	92,827
2015-02-02	Berstein David L (SVP, Chief IP Counsel)	Option Ex	29,334	.00	0
2015-02-02	Berger Harvey J M D (Chairman & CEO)	Option Ex	87,000	.00	0
2015-01-23	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.18	77,250
2015-01-22	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.16	76,987
2015-01-14	Schlesinger Sarah J. (Director)	Buy	1,300	6.25	8,125
2015-01-13	Schlesinger Sarah J. (Director)	Buy	1,300	6.97	9,061
2014-12-18	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.54	81,775
2014-12-17	Schlesinger Sarah J. (Director)	Buy	1,300	6.11	7,943
2014-12-17	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.15	76,875
2014-12-16	Schlesinger Sarah J. (Director)	Buy	1,300	6.07	7,891
2014-11-24	Cantor Maria E (SVP, Corporate Affairs and HR)	Sale	1,749	7.00	12,243
2014-11-20	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.15	76,887
2014-11-19	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.15	76,850
2014-11-12	Schlesinger Sarah J. (Director)	Buy	1,300	6.22	8,086
2014-11-11	Schlesinger Sarah J. (Director)	Buy	1,300	6.30	8,190
2014-10-16	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	5.38	67,312
2014-10-15	Schlesinger Sarah J. (Director)	Buy	1,300	5.03	6,539
2014-10-15	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	5.10	63,725
2014-10-14	Schlesinger Sarah J. (Director)	Buy	1,300	5.07	6,591
2014-09-10	Schlesinger Sarah J. (Director)	Buy	1,300	5.75	7,475
2014-09-09	Schlesinger Sarah J. (Director)	Buy	1,300	5.93	7,709
2014-09-09	Berstein David L (SVP, GC and Chief IP Officer)	Option Ex	7,825	5.23	40,924
2014-09-09	Berger Harvey J M D (Chairman & CEO)	Option Ex	150,000	5.23	784,500
2014-09-03	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.31	78,862
2014-09-02	Cantor Maria E (SVP, Corporate Affairs and HR)	Sale	2,696	6.21	16,752
2014-09-02	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Sale	56,650	6.22	352,249
2014-09-02	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	26,250	1.30	34,125
2014-09-02	Fitzgerald Edward M (Executive VP, CFO)	Sale	50,000	6.22	310,850
2014-09-02	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	50,000	5.23	261,500
2014-09-02	Berger Harvey J M D (Chairman & CEO)	Buy	12,500	6.22	77,775
2014-08-15	Denner Alexander J (Director)	Buy	850,000	5.83	4,955,500
2014-08-13	Schlesinger Sarah J. (Director)	Buy	1,300	5.71	7,423
2014-08-12	Schlesinger Sarah J. (Director)	Buy	1,300	5.52	7,175
2014-07-15	Cantor Maria E (SVP, Corporate Affairs and HR)	Option Ex	8,000	.00	0
2014-07-15	Haluska Frank (SVP, Clinical R&D, CMO)	Option Ex	8,000	.00	0
2014-07-15	Bollag Daniel M (Sr. VP, Reg. Affairs & Quality)	Option Ex	8,000	.00	0
2014-07-15	Duvall Martin J (EVP, CCO)	Option Ex	2,800	.00	0
2014-07-15	Fitzgerald Edward M (Executive VP, CFO)	Option Ex	14,000	.00	0
2014-07-15	Clackson Timothy P (President, R&D, CSO)	Option Ex	14,000	.00	0
2014-07-15	Berstein David L (SVP, GC and Chief IP Officer)	Option Ex	8,000	.00	0
2014-07-15	Berger Harvey J M D (Chairman & CEO)	Option Ex	36,800	.00	0
2014-06-02	Cantor Maria E (SVP, Corporate Affairs and HR)	Sale	3,713	6.90	25,612

Insider trading activities including stock purchases, stock sales, and option exercises of ARIA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ariad Pharmaceuticals Inc (symbol ARIA, CIK number 884731) see the Securities and Exchange Commission (SEC) website.

▪ Real-time Insider Trading

▪ Insider Officer Cluster Trading

▪ Top Officer Buys of the Week

▪ Top Officer Buys of the Month